Observed | ||||||
---|---|---|---|---|---|---|
Site of cancer (ICD9 code) | All | Male | Female | Expected | SIR | 95% CI |
Including all years of follow up | ||||||
All cancers (140–208) | 50 | 9 | 41 | 29.7 | 1.7 | 1.3 to 2.2 |
Digestive (150–154, 157) | 6 | 2 | 4 | 5.8 | 1.0 | 0.4 to 2.2 |
Liver (155) | 8 | 3 | 5 | 0.1 | 74.3 | 32.1 to 146 |
Respiratory (162) | 10 | 2 | 8 | 5.2 | 1.9 | 0.9 to 3.6 |
Breast (174) | 6 | – | 6 | 5.5 | 1.1 | 0.4 to 2.4 |
Reproductive (179–180, 182–183) | 4 | – | 4 | 2.7 | 1.5 | 0.4 to 3.8 |
Urinary (188–189) | 1 | 0 | 1 | 0.4 | 2.9 | 0.1 to 16.2 |
Haematological (200–208) | 4 | 1 | 3 | 1.5 | 2.6 | 0.7 to 6.7 |
Excluding experience in first year after PBC diagnosis | ||||||
All cancers (140–208) | 36 | 6 | 30 | 26.5 | 1.4 | 0.9 to 1.9 |
Digestive (150–154, 157) | 3 | 1 | 2 | 5.2 | 0.6 | 0.1 to 1.7 |
Liver (155) | 7 | 3 | 4 | 0.1 | 72.7 | 29.2 to 150 |
Respiratory (162) | 7 | 0 | 7 | 4.6 | 1.5 | 0.6 to 3.1 |
Breast (174) | 5 | – | 5 | 4.9 | 1.0 | 0.3 to 2.4 |
Reproductive (179–180, 182–183) | 3 | – | 3 | 2.4 | 1.3 | 0.3 to 3.7 |
Urinary (188–189) | 1 | 0 | 1 | 0.3 | 3.2 | 0.1 to 17.9 |
Haematological (200–208) | 2 | 1 | 1 | 1.4 | 1.5 | 0.2 to 5.3 |
CI, confidence interval.